Nobel Prize in Medicine goes to optogenetics, which lets light switch neurons on and off
Deisseroth, Hegemann and Nagel share the 2026 prize for turning algal light-sensing proteins into a tool that controls chosen brain cells within milliseconds.
Why it matters · For decades, neuroscience could mostly correlate brain activity with behavior. Optogenetics made it possible to test cause and effect, one cell type at a time. That change underlies much of what is now known about memory, reward and the brain's control of the body.
The 2026 Nobel Prize in Physiology or Medicine goes to Karl Deisseroth (Stanford), Peter Hegemann (Humboldt University of Berlin) and Georg Nagel (University of Würzburg) for optogenetics. The award follows the 2013 Brain Prize and the 2021 Lasker Award for the same work. Berkeley neuroscientist Hillel Adesnik calls it "a matter of when, not a matter of if."
How it works
In the early 2000s, Hegemann and Nagel discovered channelrhodopsins in single-celled algae. These proteins are ion channels that open when light hits them. Other light-activated proteins were already known, but Ofer Yizhar of the Weizmann Institute says none offered the millisecond control that channelrhodopsin does. In a 2005 Nature Neuroscience paper, since cited more than 4,700 times, Deisseroth showed that inserting these proteins into neurons lets researchers fire those neurons with flashes of light.
The key is genetic targeting. Researchers can put the proteins only into cells with a particular genetic marker, or only into cells that project to a particular brain region. Before this, electrical stimulation gave clear results only in neatly layered structures such as the hippocampus, cerebellum and retina. Adesnik says that in the cortex, where axons run everywhere, "you can't just put a microelectrode... and really know what you're stimulating." The toolbox now holds dozens of variants: fast and slow versions, red-shifted ones that respond to yellow light so two cell populations can be controlled at once, and silencers that block neurotransmitter release at axon terminals.







